Intranasal Vaccines Position NT-CoV2-1 for licensing or co-development with public health agencies and regional distributors; pursue contract manufacturing partnerships and technology licenses around the NIH/NRC licensed spike protein platform to accelerate deployment and market access.

Antibiotics Opportunity Leverage the lantibiotics program to pursue partnerships with pharma or hospital networks for MDR bacterial therapies; explore licensing, co-development, and integrative distribution agreements supported by the growing antimicrobial resistance market.

Neurotherapies Collaboration Explore opportunities to pair ONP-002 and CardioDialysis in neurology and rehabilitation markets, targeting defense, sports medicine, and clinical networks for exclusive licenses or joint development programs.

Global Trials Expansion Australia site onboarding with Bayside Health and IND readiness work with partner firms indicates paths for global multicenter trials; seek CRO collaborations and regional commercialization arrangements to accelerate global study timelines.

Strategic Partnerships The active LOI activity and press coverage signal readiness for strategic licensing and collaboration deals with larger biotech or pharma players; map target companies in infectious disease, neurology, and critical care to build a robust BD pipeline.